Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$5.7 million.

  • Insight Molecular Diagnostics' Net Cash Flow rose 340.6% to -$5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year increase of 24646.6%. This contributed to the annual value of -$796000.0 for FY2024, which is 9340.57% up from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Net Cash Flow of -$5.7 million as of Q3 2025, which was up 340.6% from -$6.7 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Net Cash Flow ranged from a high of $51.8 million in Q1 2021 and a low of -$15.2 million during Q1 2022
  • For the 5-year period, Insight Molecular Diagnostics' Net Cash Flow averaged around $603789.5, with its median value being -$4.4 million (2023).
  • Within the past 5 years, the most significant YoY rise in Insight Molecular Diagnostics' Net Cash Flow was 104184.86% (2021), while the steepest drop was 577945.21% (2021).
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Net Cash Flow stood at -$7.7 million in 2021, then plummeted by 36.39% to -$10.5 million in 2022, then skyrocketed by 58.76% to -$4.4 million in 2023, then soared by 220.71% to $5.3 million in 2024, then plummeted by 208.0% to -$5.7 million in 2025.
  • Its Net Cash Flow stands at -$5.7 million for Q3 2025, versus -$6.7 million for Q2 2025 and $22.4 million for Q1 2025.